Abbott Laboratories (Pakistan) Limited (PSX:ABOT)
Pakistan · Delayed Price · Currency is PKR 915.37
+4.19 (0.46%)
At close: Sep 17, 2026
PSX:ABOT Income Statement
Financials in millions PKR. Fiscal year is January - December.
Millions PKR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 77,016 | 75,398 | 68,177 | 55,475 | 49,258 | 42,570 | |
Revenue Growth | 6.40% | 10.59% | 22.90% | 12.62% | 15.71% | 20.65% |
Cost of Revenue | 48,503 | 48,720 | 48,283 | 43,715 | 34,821 | 26,554 |
Gross Profit | 28,513 | 26,678 | 19,894 | 11,760 | 14,436 | 16,015 |
Selling, General & Admin | 13,043 | 12,287 | 10,362 | 8,989 | 7,835 | 7,232 |
Other Operating Expenses | 1,597 | 1,444 | 862.48 | 303.19 | 590.58 | 777.55 |
Operating Expenses | 14,640 | 13,731 | 11,225 | 9,292 | 8,425 | 8,009 |
Operating Income | 13,873 | 12,947 | 8,669 | 2,468 | 6,011 | 8,006 |
Interest Expense | -64.4 | -66.46 | -11.74 | -22.18 | -25.41 | -54.48 |
Interest & Investment Income | 920.45 | 688.29 | 621.67 | 893.59 | 995.1 | 571.13 |
Currency Exchange Gain (Loss) | -90.13 | -182.3 | -16.2 | -1,341 | -779.79 | -240.34 |
Other Non Operating Income (Expenses) | 88.97 | 70.12 | 58.55 | 71.27 | 41.08 | 108.9 |
EBT Excluding Unusual Items | 14,728 | 13,457 | 9,321 | 2,069 | 6,242 | 8,392 |
Gain (Loss) on Sale of Assets | 39.6 | 113.38 | 31.14 | 20.26 | -94.33 | 18.92 |
Asset Writedown | -349.57 | -349.57 | -225.04 | - | - | - |
Other Unusual Items | 278.89 | 278.89 | - | 500.05 | - | - |
Pretax Income | 14,697 | 13,500 | 9,128 | 2,590 | 6,148 | 8,410 |
Income Tax Expense | 6,133 | 5,533 | 3,893 | 2,328 | 3,143 | 2,443 |
Net Income | 8,564 | 7,967 | 5,234 | 261.78 | 3,004 | 5,967 |
Net Income to Common | 8,564 | 7,967 | 5,234 | 261.78 | 3,004 | 5,967 |
Net Income Growth | 29.02% | 52.20% | 1899.50% | -91.29% | -49.65% | 31.57% |
Shares Outstanding (Basic) | 98 | 98 | 98 | 98 | 98 | 98 |
Shares Outstanding (Diluted) | 98 | 98 | 98 | 98 | 98 | 98 |
Shares Change | -0.00% | - | - | - | - | - |
EPS (Basic) | 87.47 | 81.37 | 53.46 | 2.67 | 30.69 | 60.95 |
EPS (Diluted) | 87.47 | 81.37 | 53.46 | 2.67 | 30.69 | 60.95 |
EPS Growth | 29.03% | 52.20% | 1899.50% | -91.29% | -49.65% | 31.57% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 5,551 | 7,441 | 1,652 | -3,137 | 212.23 | 5,768 |
Free Cash Flow Per Share | 56.70 | 76.01 | 16.87 | -32.04 | 2.17 | 58.92 |
Dividend Per Share | 40.000 | 40.000 | 10.000 | - | 15.000 | 40.000 |
Dividend Growth | 300.00% | 300.00% | - | - | -62.50% | 0% |
Gross Margin | 37.02% | 35.38% | 29.18% | 21.20% | 29.31% | 37.62% |
Operating Margin | 18.01% | 17.17% | 12.72% | 4.45% | 12.20% | 18.81% |
Profit Margin | 11.12% | 10.57% | 7.68% | 0.47% | 6.10% | 14.02% |
Free Cash Flow Margin | 7.21% | 9.87% | 2.42% | -5.65% | 0.43% | 13.55% |
EBITDA | 15,688 | 14,709 | 10,366 | 3,966 | 7,368 | 9,119 |
EBITDA Margin | 20.37% | 19.51% | 15.20% | 7.15% | 14.96% | 21.42% |
D&A For EBITDA | 1,815 | 1,762 | 1,697 | 1,498 | 1,357 | 1,113 |
EBIT | 13,873 | 12,947 | 8,669 | 2,468 | 6,011 | 8,006 |
EBIT Margin | 18.01% | 17.17% | 12.72% | 4.45% | 12.20% | 18.81% |
Effective Tax Rate | 41.73% | 40.99% | 42.65% | 89.89% | 51.13% | 29.05% |